55 related articles for article (PubMed ID: 11764665)
1. Fatigue visual analogue scale score correlates with quality of life in cancer patients receiving epoetin alfa (Sandoz) for chemotherapy-induced anaemia: The CIROCO study.
Desramé J; Baize N; Anota A; Laribi K; Stefani L; Hjiej S; Nabirotchkina E; Zelek L; Choquet S
Cancer Treat Res Commun; 2023; 37():100781. PubMed ID: 38039763
[TBL] [Abstract][Full Text] [Related]
2. Too much of a good thing.
Tonks A
BMJ; 2007 May; 334(7601):978-80. PubMed ID: 17494015
[TBL] [Abstract][Full Text] [Related]
3. HRQoL in patients receiving EV versus chemotherapy.
Masone MC
Nat Rev Urol; 2024 May; 21(5):257. PubMed ID: 38627550
[No Abstract] [Full Text] [Related]
4. Intravenous iron versus oral iron versus no iron with or without erythropoiesis- stimulating agents (ESA) for cancer patients with anaemia: a systematic review and network meta-analysis.
Adams A; Scheckel B; Habsaoui A; Haque M; Kuhr K; Monsef I; Bohlius J; Skoetz N
Cochrane Database Syst Rev; 2022 Jun; 6(6):CD012633. PubMed ID: 35724934
[TBL] [Abstract][Full Text] [Related]
5. Erythropoietin or darbepoetin for patients with cancer.
Tonia T; Mettler A; Robert N; Schwarzer G; Seidenfeld J; Weingart O; Hyde C; Engert A; Bohlius J
Cochrane Database Syst Rev; 2012 Dec; 12(12):CD003407. PubMed ID: 23235597
[TBL] [Abstract][Full Text] [Related]
6. Patients' Perceptions of Physician-Patient Discussions and Adverse Events with Cancer Therapy.
Hershman D; Calhoun E; Zapert K; Wade S; Malin J; Barron R
Arch Drug Inf; 2008 Sep; 1(2):70-78. PubMed ID: 19639029
[TBL] [Abstract][Full Text] [Related]
7. Erythropoietin or Darbepoetin for patients with cancer--meta-analysis based on individual patient data.
Bohlius J; Schmidlin K; Brillant C; Schwarzer G; Trelle S; Seidenfeld J; Zwahlen M; Clarke MJ; Weingart O; Kluge S; Piper M; Napoli M; Rades D; Steensma D; Djulbegovic B; Fey MF; Ray-Coquard I; Moebus V; Thomas G; Untch M; Schumacher M; Egger M; Engert A
Cochrane Database Syst Rev; 2009 Jul; 2009(3):CD007303. PubMed ID: 19588423
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of beta globin mRNA as an early marker of haemoglobin response to epoetin treatment.
Birgegård G; Dahl F; Glimelius B; Landegren U
Med Oncol; 2007; 24(3):318-22. PubMed ID: 17873308
[TBL] [Abstract][Full Text] [Related]
9. Patient and caregiver time burden associated with anaemia treatment in different patient populations.
Houts AC; Loh GA; Fortner BV; Kallich JD
Support Care Cancer; 2006 Dec; 14(12):1195-204. PubMed ID: 16670851
[TBL] [Abstract][Full Text] [Related]
10. The use of epoetin alfa in chemotherapy patients: a consistent profile of efficacy and safety.
Itri LM
Semin Oncol; 2002 Jun; 29(3 Suppl 8):81-7. PubMed ID: 12082659
[TBL] [Abstract][Full Text] [Related]
11. The Italian gynecological consensus statement on the use of epoetin alfa in the management of anemia.
Pecorelli S;
Semin Oncol; 2002 Jun; 29(3 Suppl 8):13-5. PubMed ID: 12082648
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and quality of life outcomes of epoetin-alpha in a double-blind, placebo-controlled, multicentre study of cancer patients receiving non-platinum-containing chemotherapy.
Littlewood TJ
Front Radiat Ther Oncol; 2002; 37():34-7. PubMed ID: 11764665
[No Abstract] [Full Text] [Related]
13. Multivariate regression analyses of data from a randomised, double-blind, placebo-controlled study confirm quality of life benefit of epoetin alfa in patients receiving non-platinum chemotherapy.
Fallowfield L; Gagnon D; Zagari M; Cella D; Bresnahan B; Littlewood TJ; McNulty P; Gorzegno G; Freund M;
Br J Cancer; 2002 Dec; 87(12):1341-53. PubMed ID: 12454760
[TBL] [Abstract][Full Text] [Related]
14. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial.
Littlewood TJ; Bajetta E; Nortier JW; Vercammen E; Rapoport B;
J Clin Oncol; 2001 Jun; 19(11):2865-74. PubMed ID: 11387359
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of epoetin alfa in a retrospective non-stratified subgroup analysis of a breast cancer cohort receiving non-platinum chemotherapy.
Bajetta E; Vercammen E; Reinhardt U; Janmohamed R; da Costa RM; Matulonis U; Guastalla JP;
Tumori; 2004; 90(5):449-57. PubMed ID: 15656327
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
